Folks . . . you guys need to re-read the Leo PR's.

Folks . . . you guys need to re-read the Leo PR's. I don't make up things, I just take CTIX more seriously than most . From 2012 year end in review LEO PR:

European trials that are being sponsored by and hosted at a leading European University (the “University”) testing Kevetrin against Acute Myelogenous Leukemia (AML) are scheduled to begin in the first half of 2013. We have been advised that the study, a phase 1b trial, will be titled “A Multi-Center, Open-Labe, Phase 1B Study of Escalating Doses of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, with Cytarabine Adminstered A) Subcutaneously, or B) Intravenously, in Patients with Acute Myelogenous Leukemia (AML).”

The University has indicated they are interested in a second study of Kevetrin in combination with a compound of a major European pharmaceutical company.  We will update shareholders as this moves forward in 2013.